Takayuki Yamamoto (T Yamamoto)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 12

Top Topics

Ulcerative Colitis

Patients Undergoing

Endoscopic Submucosal Dissection

Top Venues

Alimentary pharmacology & therapeutics

Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland

Therapeutic advances in gastroenterology

BMC gastroenterology

This page only lists publications with an associated author ORCID identifier.

Publications

Katsuyoshi Matsuoka, Tadakazu Hisamatsu, Yohei Mikami, Takayuki Yamamoto, Satoshi Motoya, Shinichiro Shinzaki, Ryuichi Iwakiri, Kenkichi Sugiura, Kunihiko Nishimura, Mika Kajita, Jovelle L Fernandez
Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study. Advances in therapy (2023)
Takayuki Yamamoto
Editorial: Is vedolizumab the preferred biologic therapy for biologic-naïve patients with ulcerative colitis? Alimentary pharmacology & therapeutics 58 (5) (2023)
Takahiro Shimoyama, Takayuki Yamamoto, Shigeyuki Yoshiyama, Ryutaro Nishikawa, Satoru Umegae
Leucine-Rich Alpha-2 Glycoprotein Is a Reliable Serum Biomarker for Evaluating Clinical and Endoscopic Disease Activity in Inflammatory Bowel Disease. Inflammatory bowel diseases (2022)
Takayuki Yamamoto, M Nakahigashi, T Shimoyama, S Umegae
Reply to Lee and Brown. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 22 (5) (2020)
Abel Botelho Quaresma, Takayuki Yamamoto, Paulo Gustavo Kotze
Biologics and surgical outcomes in Crohn's disease: is there a direct relationship? Therapeutic advances in gastroenterology 13 (2020)
Takayuki Yamamoto, Paulo Gustavo Kotze
Letter: should we delay surgery, or stop anti-TNF therapy prior to elective surgical procedures in Crohn's disease patients receiving anti-TNF agents? Alimentary pharmacology & therapeutics 50 (8) (2020)
Takayuki Yamamoto, Takahiro Shimoyama, Paulo Gustavo Kotze
Letter: is measurement of faecal biomarkers helpful for the early diagnosis and prediction of pouchitis after proctocolectomy for ulcerative colitis? Alimentary pharmacology & therapeutics 51 (1) (2020)
Takayuki Yamamoto, Paulo Gustavo Kotze
Letter: can a specific surgical approach reduce post-operative recurrence in Crohn's disease? Alimentary pharmacology & therapeutics 48 (9) (2019)
Takayuki Yamamoto, M Nakahigashi, T Shimoyama, S Umegae
Does preoperative enteral nutrition reduce the incidence of surgical complications in patients with Crohn's disease? A case-matched study. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 22 (5) (2019)
Yuen Sau Tham, Diana E Yung, Shmuel Fay, Takayuki Yamamoto, Shomron Ben-Horin, Rami Eliakim, Anastasios Koulaouzidis, Uri Kopylov
Fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn's disease: systematic review and meta-analysis. Therapeutic advances in gastroenterology 11 (2018)
Takahiro Shimoyama, Takayuki Yamamoto, Satoru Umegae, Koichi Matsumoto
Faecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing granulomonocytapheresis: a prospective cohort study. BMC gastroenterology 18 (1) (2018)
Takayuki Yamamoto, T Shimoyama
Letter: small bowel recurrence and fate of the rectum after total colectomy and ileostomy for Crohn's colitis. Alimentary pharmacology & therapeutics 45 (6) (2017)